296 related articles for article (PubMed ID: 32599075)
21. Induction of the nicotinamide riboside kinase NAD
Doig CL; Zielinska AE; Fletcher RS; Oakey LA; Elhassan YS; Garten A; Cartwright D; Heising S; Alsheri A; Watson DG; Prehn C; Adamski J; Tennant DA; Lavery GG
Skelet Muscle; 2020 Feb; 10(1):5. PubMed ID: 32075690
[TBL] [Abstract][Full Text] [Related]
22. The mitochondrial metabolic reprogramming agent trimetazidine as an 'exercise mimetic' in cachectic C26-bearing mice.
Molinari F; Pin F; Gorini S; Chiandotto S; Pontecorvo L; Penna F; Rizzuto E; Pisu S; Musarò A; Costelli P; Rosano G; Ferraro E
J Cachexia Sarcopenia Muscle; 2017 Dec; 8(6):954-973. PubMed ID: 29130633
[TBL] [Abstract][Full Text] [Related]
23. IMB0901 inhibits muscle atrophy induced by cancer cachexia through MSTN signaling pathway.
Liu D; Qiao X; Ge Z; Shang Y; Li Y; Wang W; Chen M; Si S; Chen SZ
Skelet Muscle; 2019 Mar; 9(1):8. PubMed ID: 30922397
[TBL] [Abstract][Full Text] [Related]
24. Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia.
Pin F; Barreto R; Kitase Y; Mitra S; Erne CE; Novinger LJ; Zimmers TA; Couch ME; Bonewald LF; Bonetto A
J Cachexia Sarcopenia Muscle; 2018 Aug; 9(4):685-700. PubMed ID: 30009406
[TBL] [Abstract][Full Text] [Related]
25. The histone deacetylase SIRT6 blocks myostatin expression and development of muscle atrophy.
Samant SA; Kanwal A; Pillai VB; Bao R; Gupta MP
Sci Rep; 2017 Sep; 7(1):11877. PubMed ID: 28928419
[TBL] [Abstract][Full Text] [Related]
26. Deacetylase inhibitors modulate the myostatin/follistatin axis without improving cachexia in tumor-bearing mice.
Bonetto A; Penna F; Minero VG; Reffo P; Bonelli G; Baccino FM; Costelli P
Curr Cancer Drug Targets; 2009 Aug; 9(5):608-16. PubMed ID: 19508174
[TBL] [Abstract][Full Text] [Related]
27. A novel orthotopic mouse model replicates human lung cancer cachexia.
van de Worp WRPH; Theys J; González AS; van der Heyden B; Verhaegen F; Hauser D; Caiment F; Smeets HJM; Schols AMWJ; van Helvoort A; Langen RCJ
J Cachexia Sarcopenia Muscle; 2023 Jun; 14(3):1410-1423. PubMed ID: 37025071
[TBL] [Abstract][Full Text] [Related]
28. Activin Receptor Ligand Blocking and Cancer Have Distinct Effects on Protein and Redox Homeostasis in Skeletal Muscle and Liver.
Hentilä J; Nissinen TA; Korkmaz A; Lensu S; Silvennoinen M; Pasternack A; Ritvos O; Atalay M; Hulmi JJ
Front Physiol; 2018; 9():1917. PubMed ID: 30713500
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia.
Silva KA; Dong J; Dong Y; Dong Y; Schor N; Tweardy DJ; Zhang L; Mitch WE
J Biol Chem; 2015 Apr; 290(17):11177-87. PubMed ID: 25787076
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs.
Barreto R; Waning DL; Gao H; Liu Y; Zimmers TA; Bonetto A
Oncotarget; 2016 Jul; 7(28):43442-43460. PubMed ID: 27259276
[TBL] [Abstract][Full Text] [Related]
31. Exercise restores decreased physical activity levels and increases markers of autophagy and oxidative capacity in myostatin/activin-blocked mdx mice.
Hulmi JJ; Oliveira BM; Silvennoinen M; Hoogaars WM; Pasternack A; Kainulainen H; Ritvos O
Am J Physiol Endocrinol Metab; 2013 Jul; 305(2):E171-82. PubMed ID: 23695214
[TBL] [Abstract][Full Text] [Related]
32. Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia.
Fukawa T; Yan-Jiang BC; Min-Wen JC; Jun-Hao ET; Huang D; Qian CN; Ong P; Li Z; Chen S; Mak SY; Lim WJ; Kanayama HO; Mohan RE; Wang RR; Lai JH; Chua C; Ong HS; Tan KK; Ho YS; Tan IB; Teh BT; Shyh-Chang N
Nat Med; 2016 Jun; 22(6):666-71. PubMed ID: 27135739
[TBL] [Abstract][Full Text] [Related]
33. 2-Deoxy-D-glucose Alleviates Cancer Cachexia-Induced Muscle Wasting by Enhancing Ketone Metabolism and Inhibiting the Cori Cycle.
Wei L; Wang R; Wazir J; Lin K; Song S; Li L; Pu W; Zhao C; Wang Y; Su Z; Wang H
Cells; 2022 Sep; 11(19):. PubMed ID: 36230949
[TBL] [Abstract][Full Text] [Related]
34. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.
Sun R; Zhang S; Hu W; Lu X; Lou N; Yang Z; Chen S; Zhang X; Yang H
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C101-15. PubMed ID: 27122162
[TBL] [Abstract][Full Text] [Related]
35. Metabolic derangements of skeletal muscle from a murine model of glioma cachexia.
Cui P; Shao W; Huang C; Wu CJ; Jiang B; Lin D
Skelet Muscle; 2019 Jan; 9(1):3. PubMed ID: 30635036
[TBL] [Abstract][Full Text] [Related]
36. Molecular mechanisms of cancer cachexia-related loss of skeletal muscle mass: data analysis from preclinical and clinical studies.
Martin A; Gallot YS; Freyssenet D
J Cachexia Sarcopenia Muscle; 2023 Jun; 14(3):1150-1167. PubMed ID: 36864755
[TBL] [Abstract][Full Text] [Related]
37. [Role of Activin A and Myostatin in cancer cachexia].
Thissen JP; Loumaye A
Ann Endocrinol (Paris); 2013 May; 74(2):79-81. PubMed ID: 23566617
[TBL] [Abstract][Full Text] [Related]
38. Myostatin/activin pathway antagonism: molecular basis and therapeutic potential.
Han HQ; Zhou X; Mitch WE; Goldberg AL
Int J Biochem Cell Biol; 2013 Oct; 45(10):2333-47. PubMed ID: 23721881
[TBL] [Abstract][Full Text] [Related]
39. Activin A-Induced Cachectic Wasting Is Attenuated by Systemic Delivery of Its Cognate Propeptide in Male Mice.
Walton KL; Chen JL; Arnold Q; Kelly E; La M; Lu L; Lovrecz G; Hagg A; Colgan TD; Qian H; Gregorevic P; Harrison CA
Endocrinology; 2019 Oct; 160(10):2417-2426. PubMed ID: 31322699
[TBL] [Abstract][Full Text] [Related]
40. Females display relatively preserved muscle quality compared with males during the onset and early stages of C26-induced cancer cachexia.
Cabrera AR; Deaver JW; Lim S; Morena da Silva F; Schrems ER; Saling LW; Tsitkanou S; Rosa-Caldwell ME; Wiggs MP; Washington TA; Greene NP
J Appl Physiol (1985); 2023 Sep; 135(3):655-672. PubMed ID: 37535708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
